中欧和东欧各国的麻风病--2022 年爆发

IF 6.3 3区 医学 Q1 INFECTIOUS DISEASES
Irina Ianache , Agata Skrzat-Klapaczynska , David Jilich , Lukas Fleischhans , Ivana Gmizic , Jovan Ranin , Antonios Papadopoulos , Konstantinos Protopapas , Velida Mulabdic , Botond Lakatos , Eva Livia Nagy , Josip Begovac , Tiberiu Holban , Dilek Yildiz Sevgi , Alma Cicic , Nina Yancheva , Lubomir Sojak , Nino Rukhadze , Justyna Kowalska , Cristiana Oprea
{"title":"中欧和东欧各国的麻风病--2022 年爆发","authors":"Irina Ianache ,&nbsp;Agata Skrzat-Klapaczynska ,&nbsp;David Jilich ,&nbsp;Lukas Fleischhans ,&nbsp;Ivana Gmizic ,&nbsp;Jovan Ranin ,&nbsp;Antonios Papadopoulos ,&nbsp;Konstantinos Protopapas ,&nbsp;Velida Mulabdic ,&nbsp;Botond Lakatos ,&nbsp;Eva Livia Nagy ,&nbsp;Josip Begovac ,&nbsp;Tiberiu Holban ,&nbsp;Dilek Yildiz Sevgi ,&nbsp;Alma Cicic ,&nbsp;Nina Yancheva ,&nbsp;Lubomir Sojak ,&nbsp;Nino Rukhadze ,&nbsp;Justyna Kowalska ,&nbsp;Cristiana Oprea","doi":"10.1016/j.tmaid.2024.102719","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The aim of the study was to assess socio-demographical characteristics, clinical presentation, and outcomes in patients diagnosed with mpox.</p></div><div><h3>Methods</h3><p>A survey on patients diagnosed with mpox was performed in 14 countries from Central and Eastern Europe. Data was compared according to HIV status and country of origin (EU vs. non-EU). Mpox diagnosis was confirmed by RT-PCR from oropharyngeal swabs, skin lesions, and other body fluids.</p></div><div><h3>Results</h3><p>Out of 154 patients confirmed with mpox in 2022, 99.3% were males, with a median age (years) of 35 (IQR 30–39), 90.2% MSM and 48.7% PLWH. Compared to HIV-negative subjects, PLWH had more frequent high-risk behaviours:chemsex (p = 0.015), group sex (p = 0.027), and a history of sexually transmitted infections (STIs) (p = 0.004). Persons from EU were more often PLWH (p = 0.042), MSM (p &lt; 0.0001), had multiple sexual partners (p = 0.025), practiced chemsex (p = 0.008) or group-sex (p = 0.005) and had more often history of STIs (p &lt; 0.0001). The median CD4 cell count/mL at mpox diagnosis was 713 (IQR 486–996) and 73.5% had undetectable HIV VL. The commonest clinical features were fever (108 cases), lymphadenopathy (78), and vesiculo-pustular rash: penile (76), perianal (48), limbs (67). Fifty-one (31%) persons were hospitalized due to complications or epidemiological reasons. Three patients received tecovirimat or cidofovir. The outcome was favorable for all patients, including 4 with severe forms.</p></div><div><h3>Conclusions</h3><p>Mpox was diagnosed predominantly in young MSM, with high-risk behaviors and history of STIs. Effective contact tracing and vaccination are important strategic pillars to control mpox outbreaks.</p></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"59 ","pages":"Article 102719"},"PeriodicalIF":6.3000,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1477893924000334/pdfft?md5=9d886ddc4897f3065cabcba454750587&pid=1-s2.0-S1477893924000334-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Mpox across countries from Central and Eastern Europe - 2022 outbreak\",\"authors\":\"Irina Ianache ,&nbsp;Agata Skrzat-Klapaczynska ,&nbsp;David Jilich ,&nbsp;Lukas Fleischhans ,&nbsp;Ivana Gmizic ,&nbsp;Jovan Ranin ,&nbsp;Antonios Papadopoulos ,&nbsp;Konstantinos Protopapas ,&nbsp;Velida Mulabdic ,&nbsp;Botond Lakatos ,&nbsp;Eva Livia Nagy ,&nbsp;Josip Begovac ,&nbsp;Tiberiu Holban ,&nbsp;Dilek Yildiz Sevgi ,&nbsp;Alma Cicic ,&nbsp;Nina Yancheva ,&nbsp;Lubomir Sojak ,&nbsp;Nino Rukhadze ,&nbsp;Justyna Kowalska ,&nbsp;Cristiana Oprea\",\"doi\":\"10.1016/j.tmaid.2024.102719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The aim of the study was to assess socio-demographical characteristics, clinical presentation, and outcomes in patients diagnosed with mpox.</p></div><div><h3>Methods</h3><p>A survey on patients diagnosed with mpox was performed in 14 countries from Central and Eastern Europe. Data was compared according to HIV status and country of origin (EU vs. non-EU). Mpox diagnosis was confirmed by RT-PCR from oropharyngeal swabs, skin lesions, and other body fluids.</p></div><div><h3>Results</h3><p>Out of 154 patients confirmed with mpox in 2022, 99.3% were males, with a median age (years) of 35 (IQR 30–39), 90.2% MSM and 48.7% PLWH. Compared to HIV-negative subjects, PLWH had more frequent high-risk behaviours:chemsex (p = 0.015), group sex (p = 0.027), and a history of sexually transmitted infections (STIs) (p = 0.004). Persons from EU were more often PLWH (p = 0.042), MSM (p &lt; 0.0001), had multiple sexual partners (p = 0.025), practiced chemsex (p = 0.008) or group-sex (p = 0.005) and had more often history of STIs (p &lt; 0.0001). The median CD4 cell count/mL at mpox diagnosis was 713 (IQR 486–996) and 73.5% had undetectable HIV VL. The commonest clinical features were fever (108 cases), lymphadenopathy (78), and vesiculo-pustular rash: penile (76), perianal (48), limbs (67). Fifty-one (31%) persons were hospitalized due to complications or epidemiological reasons. Three patients received tecovirimat or cidofovir. The outcome was favorable for all patients, including 4 with severe forms.</p></div><div><h3>Conclusions</h3><p>Mpox was diagnosed predominantly in young MSM, with high-risk behaviors and history of STIs. Effective contact tracing and vaccination are important strategic pillars to control mpox outbreaks.</p></div>\",\"PeriodicalId\":23312,\"journal\":{\"name\":\"Travel Medicine and Infectious Disease\",\"volume\":\"59 \",\"pages\":\"Article 102719\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1477893924000334/pdfft?md5=9d886ddc4897f3065cabcba454750587&pid=1-s2.0-S1477893924000334-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Travel Medicine and Infectious Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1477893924000334\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Travel Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1477893924000334","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景该研究旨在评估确诊为水痘患者的社会人口学特征、临床表现和治疗效果。方法在中欧和东欧的 14 个国家对确诊为水痘的患者进行了调查。根据艾滋病病毒感染状况和原籍国(欧盟与非欧盟)对数据进行了比较。结果在 2022 年确诊的 154 名麻风病人中,99.3% 为男性,中位年龄(岁)为 35(IQR 30-39),90.2% 为 MSM,48.7% 为 PLWH。与HIV阴性受试者相比,PLWH有更频繁的高危行为:药交(p = 0.015)、群交(p = 0.027)和性传播感染(STI)病史(p = 0.004)。来自欧盟的人更多是 PLWH (p = 0.042)、MSM (p < 0.0001)、有多个性伴侣 (p = 0.025)、进行化学性交 (p = 0.008) 或群交 (p = 0.005),并且更多有性传播感染病史 (p < 0.0001)。确诊为 mpox 时 CD4 细胞计数/毫升的中位数为 713(IQR 486-996),73.5% 的患者检测不到 HIV VL。最常见的临床特征是发热(108 例)、淋巴结病(78 例)和水泡性脓疱疹:阴茎(76 例)、肛周(48 例)和四肢(67 例)。51人(31%)因并发症或流行病学原因住院治疗。三名患者接受了替考韦酯或西多福韦酯治疗。结论天花主要在年轻的男男性行为者中确诊,他们有高危行为和性传播感染史。有效的接触追踪和疫苗接种是控制天花爆发的重要战略支柱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mpox across countries from Central and Eastern Europe - 2022 outbreak

Background

The aim of the study was to assess socio-demographical characteristics, clinical presentation, and outcomes in patients diagnosed with mpox.

Methods

A survey on patients diagnosed with mpox was performed in 14 countries from Central and Eastern Europe. Data was compared according to HIV status and country of origin (EU vs. non-EU). Mpox diagnosis was confirmed by RT-PCR from oropharyngeal swabs, skin lesions, and other body fluids.

Results

Out of 154 patients confirmed with mpox in 2022, 99.3% were males, with a median age (years) of 35 (IQR 30–39), 90.2% MSM and 48.7% PLWH. Compared to HIV-negative subjects, PLWH had more frequent high-risk behaviours:chemsex (p = 0.015), group sex (p = 0.027), and a history of sexually transmitted infections (STIs) (p = 0.004). Persons from EU were more often PLWH (p = 0.042), MSM (p < 0.0001), had multiple sexual partners (p = 0.025), practiced chemsex (p = 0.008) or group-sex (p = 0.005) and had more often history of STIs (p < 0.0001). The median CD4 cell count/mL at mpox diagnosis was 713 (IQR 486–996) and 73.5% had undetectable HIV VL. The commonest clinical features were fever (108 cases), lymphadenopathy (78), and vesiculo-pustular rash: penile (76), perianal (48), limbs (67). Fifty-one (31%) persons were hospitalized due to complications or epidemiological reasons. Three patients received tecovirimat or cidofovir. The outcome was favorable for all patients, including 4 with severe forms.

Conclusions

Mpox was diagnosed predominantly in young MSM, with high-risk behaviors and history of STIs. Effective contact tracing and vaccination are important strategic pillars to control mpox outbreaks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Travel Medicine and Infectious Disease
Travel Medicine and Infectious Disease PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-INFECTIOUS DISEASES
CiteScore
19.40
自引率
1.70%
发文量
211
审稿时长
49 days
期刊介绍: Travel Medicine and Infectious Disease Publication Scope: Publishes original papers, reviews, and consensus papers Primary theme: infectious disease in the context of travel medicine Focus Areas: Epidemiology and surveillance of travel-related illness Prevention and treatment of travel-associated infections Malaria prevention and treatment Travellers' diarrhoea Infections associated with mass gatherings Migration-related infections Vaccines and vaccine-preventable disease Global policy/regulations for disease prevention and control Practical clinical issues for travel and tropical medicine practitioners Coverage: Addresses areas of controversy and debate in travel medicine Aims to inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease Publication Features: Offers a fast peer-review process Provides early online publication of accepted manuscripts Aims to publish cutting-edge papers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信